BLIN — what changed in the latest 10-Q
A section-by-section comparison of BLIN's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-13 vs the prior 10-Q · 2026-05-15
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +21 | −17 | ~47 | 36 |
| Controls & procedures | Text added/removed | 0 | 0 | ~1 | 2 |
| Legal proceedings | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-13
The decrease with the prior comparable periods is primarily attributable to lower personnel costs.
Research and development expenses of $0.9 million for the three months ended June 30, 2026 remained consistent with the three months ended June 30, 2025.
Research and development expenses as a percentage of total revenue was 24% and 25% for the three months ended June 30, 2026 and 2025, respectively.
Research and development expenses of $2.6 million for the nine months ended June 30, 2026 decreased from $3.1 million for the nine months ended June 30, 2025.
Research and development expenses as a percentage of total revenue was 22% and 27% for the nine months ended June 30, 2026 and 2025, respectively.
Text removed vs the prior filing · source: 10-Q · 2026-05-15
Research and development expenses as a percentage of total revenue was 22% and 29% for the three months ended March 31, 2026 and 2025, respectively.
Research and development expenses of $1.7 million for the six months ended March 31, 2026 decreased from $2.2 million for the six months ended March 31, 2025.
Research and development expenses as a percentage of total revenue was 21% and 28% for the six months ended March 31, 2026 and 2025, respectively.
The decrease from the prior comparable periods is primarily attributable to lower personnel costs.
Depreciation and amortization expenses of $0.2 million for the three months ended March 31, 2026 remained consistent with the three months ended March 31, 2025.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice